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Letters to the Editor
A mutation in exon 7 of the human cytochrome
P-4501Al gene as marker for sensitivity to
anti-cancer drugs?
Sir
One of the major problems in the anti-cancer drug treatment of
patients with malignant tumours is the development ofanti-cancer
drug resistance. Evidence is accumulating that anti-cancer drug
resistance is a multifactorial phenomenon, and (a combination of)
several different mechanisms may be responsible for the drug-
resistant phenotype, such as an altered expression ofdrug-metabo-
lizing enzymes in tumour cells. Among other changes, compared
with the parent MCF-7 WT (wild type) cells (Davies et al, 1996),
low inducibility ofcytochrome P-4501AI (CYPIA1) and elevated
expression of glutathione S-transferase have been detected in
multidrug-resistant MCF-7 Adr breast cancer cells (Ivy et al,
1988). Many anti-cancer drugs require prior metabolic activation
by CYP enzymes and, consequently, low CYP activities could
result in cells being insensitive to these agents (LeBlanc and
Waxman, 1989; Chen et al, 1996). On the other hand, enhance-
ment of detoxification of the anti-cancer drugs by glutathione S-
transferases may also result in less efficient cytotoxic damage of
tumour cells (Hayes and Pulford, 1995).
Figure Detection of exon-7 CYPlAl polymorphism by PCR. The presence
of the CYPlAl exon 7 mutation was investigated by PCR and restriction
enzyme digestion with Ncol, essentially as described by Sheilds et al, 1993.
The polymerase chain reaction was used to amplify 195-base pair fragments.
Wild type genes were identified by the presence of a Ncol restriction site
yielding 32- and 163-base pair fragments, while the mutant gene missed this
restriction site. Lane 1, DNA size markers; lane 2, drug resistant MCF-7 Adr
PCR fragments after Ncol digestion (163 base pair fragments; 32 base pair
fragments are not visible); lane 3, drug sensitive MCF-7 WT PCR fragments
after Ncol digestion (both 195 and 163 base pair fragments, corresponding
with heterozygote mutant genotype)
A point mutation in exon 7 ofthe human CYPIAJ gene has been
described which results in an isoleucine to valine substitution
(Hayashi et al, 1991) and leads to an enhancement of CYPIAl
enzyme activity (Crofts et al, 1994); this can lead to a more efficient
activation of anti-cancer drugs (LeBlanc and Waxman, 1989). This
phenotype is present in the drug-sensitive MCF-7 WT breast cancer
cells (Figure). The MCF-7 Adr multidrug-resistant cells, however,
possess the non-mutated CYPIAl genotype (Figure 1). This may
explain the observed CYP1Al inducibility ofthe MCF-7 WT cells,
which is absent in the MCF-7 Adr cell line (Ivy et al, 1988). As
discussed above, deficient (inducibility of) CYPIAI enzyme
activity could lead to failure in activation of anti-cancer drugs and
thus contribute to drug resistance.
In conclusion, it may be of importance to investigate a possible
relationship between the mutation in exon 7 of the CYPIAl gene
(which is present in about 17% of Dutch Caucasians) and clinical
sensitivity to particular (regimens of) anti-cancer drugs. The rapid
polymerase chain reaction method for detection of this poly-
morphism, as applied above, could then be of value in selecting
patients for chemotherapy.
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